Cargando…
Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D
[Image: see text] Insulin icodec (icodec) is a once-weekly basal insulin in development. This post hoc analysis used data from the NCT03951805 trial to investigate CGM-derived time in, above, below range (TIR, TAR, TBR) and glycemic variability measured as coefficient of variation (CV%). Insulin-naï...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067857/ http://dx.doi.org/10.4103/2230-8210.342288 |
_version_ | 1784700101403344896 |
---|---|
author | Kunder, Sushil Lingvay, Ildiko Bang, Rikke Beck Koefoed, Mette M Mader, Julia K Pettus, Jeremy Wagner, Lily Mathieu, Chantal |
author_facet | Kunder, Sushil Lingvay, Ildiko Bang, Rikke Beck Koefoed, Mette M Mader, Julia K Pettus, Jeremy Wagner, Lily Mathieu, Chantal |
author_sort | Kunder, Sushil |
collection | PubMed |
description | [Image: see text] Insulin icodec (icodec) is a once-weekly basal insulin in development. This post hoc analysis used data from the NCT03951805 trial to investigate CGM-derived time in, above, below range (TIR, TAR, TBR) and glycemic variability measured as coefficient of variation (CV%). Insulin-naïve patients with T2D (N=205) received insulin glargine U100 (IGlar U100; pre-breakfast SMBG target 80-130 mg/dL, adjusted ±4U/day), icodec titration A (80- 130 mg/dL, ±21U/week), B (80-130 mg/dL, ±28U/week; most relevant comparator to IGlar U100), or C (70-108 mg/dL, ±28U/week). Treatments were titrated weekly. TIR (70-180 mg/dL), TAR (>180 mg/dL), TBR (<70 and <54 mg/dL) and CV% were calculated during the 2-week screening and the 16-week treatment periods using double-blinded Dexcom G6 CGM data. During the trial, across arms, TIR increased to >70% from weeks 7 and 8, TAR decreased to <25% from weeks 11 and 12, TBR and TBR remained below the recommended targets (<4% and <1). At weeks 15 and 16, proportion of patients achieving >70% TIR and TBR <4% were 63.3% for titration A, 80.0% for B, 66.0% for C and 64.0% for IGlar U100. CV% increased slightly over time but remained <36% in all arms. TIR increased during the trial across treatments, and similar or numerically higher proportion of patients achieved >70% TIR and TBR <4% with icodecvs. IGlar U100 at weeks 15 and 16 |
format | Online Article Text |
id | pubmed-9067857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-90678572022-05-05 Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D Kunder, Sushil Lingvay, Ildiko Bang, Rikke Beck Koefoed, Mette M Mader, Julia K Pettus, Jeremy Wagner, Lily Mathieu, Chantal Indian J Endocrinol Metab Abstracts … Esicon 2021 [Image: see text] Insulin icodec (icodec) is a once-weekly basal insulin in development. This post hoc analysis used data from the NCT03951805 trial to investigate CGM-derived time in, above, below range (TIR, TAR, TBR) and glycemic variability measured as coefficient of variation (CV%). Insulin-naïve patients with T2D (N=205) received insulin glargine U100 (IGlar U100; pre-breakfast SMBG target 80-130 mg/dL, adjusted ±4U/day), icodec titration A (80- 130 mg/dL, ±21U/week), B (80-130 mg/dL, ±28U/week; most relevant comparator to IGlar U100), or C (70-108 mg/dL, ±28U/week). Treatments were titrated weekly. TIR (70-180 mg/dL), TAR (>180 mg/dL), TBR (<70 and <54 mg/dL) and CV% were calculated during the 2-week screening and the 16-week treatment periods using double-blinded Dexcom G6 CGM data. During the trial, across arms, TIR increased to >70% from weeks 7 and 8, TAR decreased to <25% from weeks 11 and 12, TBR and TBR remained below the recommended targets (<4% and <1). At weeks 15 and 16, proportion of patients achieving >70% TIR and TBR <4% were 63.3% for titration A, 80.0% for B, 66.0% for C and 64.0% for IGlar U100. CV% increased slightly over time but remained <36% in all arms. TIR increased during the trial across treatments, and similar or numerically higher proportion of patients achieved >70% TIR and TBR <4% with icodecvs. IGlar U100 at weeks 15 and 16 Wolters Kluwer - Medknow 2022-03 /pmc/articles/PMC9067857/ http://dx.doi.org/10.4103/2230-8210.342288 Text en Copyright: © 2022 Indian Journal of Endocrinology and Metabolism https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Abstracts … Esicon 2021 Kunder, Sushil Lingvay, Ildiko Bang, Rikke Beck Koefoed, Mette M Mader, Julia K Pettus, Jeremy Wagner, Lily Mathieu, Chantal Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D |
title | Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D |
title_full | Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D |
title_fullStr | Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D |
title_full_unstemmed | Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D |
title_short | Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D |
title_sort | abstract 3: cgm-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine u100 in insulin-naïve patients with t2d |
topic | Abstracts … Esicon 2021 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067857/ http://dx.doi.org/10.4103/2230-8210.342288 |
work_keys_str_mv | AT kundersushil abstract3cgmderivedparametersforonceweeklyinsulinicodecversusoncedailyinsulinglargineu100ininsulinnaivepatientswitht2d AT lingvayildiko abstract3cgmderivedparametersforonceweeklyinsulinicodecversusoncedailyinsulinglargineu100ininsulinnaivepatientswitht2d AT bangrikkebeck abstract3cgmderivedparametersforonceweeklyinsulinicodecversusoncedailyinsulinglargineu100ininsulinnaivepatientswitht2d AT koefoedmettem abstract3cgmderivedparametersforonceweeklyinsulinicodecversusoncedailyinsulinglargineu100ininsulinnaivepatientswitht2d AT maderjuliak abstract3cgmderivedparametersforonceweeklyinsulinicodecversusoncedailyinsulinglargineu100ininsulinnaivepatientswitht2d AT pettusjeremy abstract3cgmderivedparametersforonceweeklyinsulinicodecversusoncedailyinsulinglargineu100ininsulinnaivepatientswitht2d AT wagnerlily abstract3cgmderivedparametersforonceweeklyinsulinicodecversusoncedailyinsulinglargineu100ininsulinnaivepatientswitht2d AT mathieuchantal abstract3cgmderivedparametersforonceweeklyinsulinicodecversusoncedailyinsulinglargineu100ininsulinnaivepatientswitht2d |